Your session is about to expire
← Back to Search
LPRI424 (dienogest/ethinylestradiol) for Birth Control
Study Summary
This trial is testing a new contraceptive drug to see if it is effective and safe.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have stopped having your period for no clear reason.You have had trouble getting pregnant in the past.You have been diagnosed with polycystic ovary syndrome (PCOS).
- Group 1: LPRI424
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this experiment involve any geriatric patients?
"The minimum age for participation in this clinical trial is 15 and the maximum age is 45, as specified in the inclusion criteria."
What other research has included LPRI424 (dienogest/ethinylestradiol) in their investigations?
"LPRI424 (dienogest/ethinylestradiol) is being trialed in 17 different locations. Out of the 17 clinical trials, 2 have progressed to Phase 3. Although the majority of research is being conducted in Savannah, Georgia, there are other locations running similar trials."
Who is this study most likely to benefit?
"Eligible participants for this research should be using some form of contraception and between the ages of 15-45. This particular clinical trial is looking for around 1034 individuals."
Are there documented risks associated with the use of LPRI424 (dienogest/ethinylestradiol)?
"LPRI424 (dienogest/ethinylestradiol) is a medication that has been studied in Phase 3 clinical trials. This denotes that while there is some evidence of efficacy, multiple rounds of data have gone into supporting its safety. Our team rates it as a 3."
Share this study with friends
Copy Link
Messenger